Theravance Biopharma (TBPH) Income from Continuing Operations (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Income from Continuing Operations of 4970000.0 for Q1 2026, up 63.4% year-over-year from 3041627.46 in Q1 2025, and down 117.35% quarter-over-quarter from 28648000.0 in Q4 2025.
Theravance Biopharma (TBPH) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Income from Continuing Operations for 14 consecutive years, with 4970000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 63.4% year-over-year to 4970000.0; the TTM figure through Mar 2026 stood at 82128000.0 (up 240.79% YoY), while the FY2025 annual figure was 73519000.0, up 230.31% from the prior year.
- Income from Continuing Operations fell to 4970000.0 in Q1 2026 per TBPH's latest filing, from 28648000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 54835000.0 in Q2 2025 and bottomed at 40259000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 7804647.06 across 5 years, with a median of 13579000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 192.8% — and 2025, when it soared 431.75%.
- Theravance Biopharma's Income from Continuing Operations stood at 14256000.0 in 2022, then soared by 62.8% to 5303000.0 in 2023, then tumbled by 192.8% to 15527000.0 in 2024, then jumped by 284.5% to 28648000.0 in 2025, then sank by 117.35% to 4970000.0 in 2026.
- Business Quant data shows TBPH's Income from Continuing Operations at 4970000.0 in Q1 2026, 28648000.0 in Q4 2025, and 3615000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -5.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.90 Mn |
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | 28.65 Mn |
| Sep 30, 2025 | 3.62 Mn |
| Jun 30, 2025 | 54.84 Mn |
| Mar 31, 2025 | -13.58 Mn |
| Dec 31, 2024 | -15.53 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | -16.53 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -5.30 Mn |
| Sep 30, 2023 | -8.95 Mn |
| Jun 30, 2023 | -15.65 Mn |
| Mar 31, 2023 | -22.09 Mn |
| Dec 31, 2022 | -14.26 Mn |
| Sep 30, 2022 | -15.52 Mn |
| Jun 30, 2022 | -22.79 Mn |
| Mar 31, 2022 | -40.26 Mn |
| Dec 31, 2021 | -57.77 Mn |
| Sep 30, 2021 | -55.91 Mn |